Conjugués anticorps-médicament, Thérapie cellulaire, Autre, Dégradeurs de protéines ciblés
June 19, 2026
Rupert Vessey, PhD and member of our Scientific Advisory Board, joins Christopher Ung, our Chief Scientific Business Officer, for a conversation on how companies decide where to invest when multiple modalities target the same biology.
